New combo therapy shows promise for advanced skin cancer
NCT ID NCT05309421
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 29 times
Summary
This trial tests a new drug, EVX-01, combined with the standard immunotherapy pembrolizumab in 17 adults with advanced melanoma that cannot be removed by surgery. The goal is to see if adding EVX-01 improves tumor shrinkage compared to historical data with pembrolizumab alone. Participants must not have received checkpoint inhibitor treatment before.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Divisione di Oncologia Medica del Melanoma
Milan, Italy
-
Instituto Nazionale Tumori IRCCS Fondazione
Naples, Italy
-
Melanoma Institute Australia
Wollstonecraft, New South Wales, 2065, Australia
-
One Clinical Research
Nedlands, Western Australia, 6009, Australia
Conditions
Explore the condition pages connected to this study.